On December 19, Evercore ISI analyst Mark Mahaney reaffirmed an outperform rating for ODDITY Tech (NASDAQ:ODD). He set a price target of $80, representing a potential upside of nearly 126%.
Mahaney noted the stock's valuation appears attractive. He highlighted the company's latest skin care offering, METHODIQ, pointing to website visits and customer reviews that indicate a promising response.
Based on his analysis, Mahaney believes METHODIQ could generate incremental revenues between $80 million and $200 million by 2028.
The analyst also observed Oddity's strong fundamental performance. He cited financial discipline and customer retention, with the company delivering EBITDA margins of nearly 20% for nine consecutive quarters. Topline growth has exceeded 20% for ten consecutive quarters.
Earlier, on December 17, Citizens also reiterated a bullish stance by assigning an outperform rating to ODDITY Tech. The firm similarly estimated a 126% upside based on an $80 price target.
Citizens focused on a favorable market response for METHODIQ. The firm stated that, on a relative basis, METHODIQ has outperformed the SpoiledChild product at a comparable stage. This performance is seen as paving the way for further growth and cross-selling opportunities.
ODDITY Tech is a consumer technology business operating in the beauty and wellness industries. Its platform utilizes data science, machine learning, and biotechnology to develop digital-first brands like SpoiledChild and IL MAKIAGE.